BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and evaluation of novel pyrimidinylaminothiophene derivatives as FGFR1 inhibitors against human glioblastoma multiforme. 2023

Yong-Liang Li, and Long-Jia Yan, and Hui-Xiong Chen, and Ban-Kang Ruan, and Pascal Dao, and Zhi-Yun Du, and Chang-Zhi Dong, and Bernard Meunier
School of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou, PR China.

Vascular endothelial growth factor receptors (VEGFRs) have emerged as the most promising anti-angiogenic therapeutic targets for the treatment of recurrent glioblastomas (GBM). However, anti-VEGF treatments led to the high proportion of non-responder patients or non lasting clinical response and the tumor progression to the greater malignant stage. To overcome these problems, there is an utmost need to develop innovative anti-angiogenic therapies. In this study, we report the development of a series of new FGFR1 inhibitors. Among them, compound 4i was able to potently inhibit FGFR1 kinase activities both in vitro and in vivo. This compound displayed strong anti-angiogenic activity in HUVECs and anti-tumor growth and anti-invasion effects in U-87MG cell line. These results emphasize the importance of FGFR1-mediated signaling pathways in GBM and reveal that pharmacological inhibition of FGFR1 can enhance the anti-tumoral, anti-angiogenic and anti-metastatic efficiency against GBM. These data support targeting of FGFR1 as a novel anti-angiogenic strategy and highlight the potential of compound 4i as a promising anti-angiogenic and anti-metastatic candidate for GBM therapy.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D042461 Vascular Endothelial Growth Factor A The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced. Vascular Endothelial Growth Factor,Vascular Endothelial Growth Factor-A,GD-VEGF,Glioma-Derived Vascular Endothelial Cell Growth Factor,VEGF,VEGF-A,Vascular Permeability Factor,Vasculotropin,Glioma Derived Vascular Endothelial Cell Growth Factor,Permeability Factor, Vascular
D051496 Receptor, Fibroblast Growth Factor, Type 1 A fibroblast growth factor receptor with specificity for FIBROBLAST GROWTH FACTORS; HEPARAN SULFATE PROTEOGLYCAN; and NEURONAL CELL ADHESION MOLECULES. Several variants of the receptor exist due to multiple ALTERNATIVE SPLICING of its mRNA. Fibroblast growth factor receptor 1 contains three extracellular IMMUNOGLOBULIN C2-SET DOMAINS and is a tyrosine kinase that transmits signals through the MAP KINASE SIGNALING SYSTEM. Fibroblast Growth Factor Receptor 1,CD331 Antigen,FGFR1 Protein,FGFR1 Tyrosine Kinase,Fibroblast Growth Factor Soluble Receptor 1,fms-Like Tyrosine Kinase-2,Antigen, CD331,fms Like Tyrosine Kinase 2

Related Publications

Yong-Liang Li, and Long-Jia Yan, and Hui-Xiong Chen, and Ban-Kang Ruan, and Pascal Dao, and Zhi-Yun Du, and Chang-Zhi Dong, and Bernard Meunier
Design, synthesis and biological evaluation of naphthostyril derivatives as novel protein kinase FGFR1 inhibitors.
February 2015, Journal of enzyme inhibition and medicinal chemistry,
Yong-Liang Li, and Long-Jia Yan, and Hui-Xiong Chen, and Ban-Kang Ruan, and Pascal Dao, and Zhi-Yun Du, and Chang-Zhi Dong, and Bernard Meunier
Design, synthesis and biological evaluation of benzimidazole derivatives as novel human Pin1 inhibitors.
July 2019, Bioorganic & medicinal chemistry letters,
Yong-Liang Li, and Long-Jia Yan, and Hui-Xiong Chen, and Ban-Kang Ruan, and Pascal Dao, and Zhi-Yun Du, and Chang-Zhi Dong, and Bernard Meunier
Design, synthesis, and biological evaluation of 3-vinyl-quinoxalin-2(1H)-one derivatives as novel antitumor inhibitors of FGFR1.
January 2016, Drug design, development and therapy,
Yong-Liang Li, and Long-Jia Yan, and Hui-Xiong Chen, and Ban-Kang Ruan, and Pascal Dao, and Zhi-Yun Du, and Chang-Zhi Dong, and Bernard Meunier
Design, synthesis, and evaluation of benzophenone derivatives as novel acetylcholinesterase inhibitors.
March 2009, European journal of medicinal chemistry,
Yong-Liang Li, and Long-Jia Yan, and Hui-Xiong Chen, and Ban-Kang Ruan, and Pascal Dao, and Zhi-Yun Du, and Chang-Zhi Dong, and Bernard Meunier
Design, synthesis and evaluation of novel indole derivatives as AKT inhibitors.
January 2014, Bioorganic & medicinal chemistry,
Yong-Liang Li, and Long-Jia Yan, and Hui-Xiong Chen, and Ban-Kang Ruan, and Pascal Dao, and Zhi-Yun Du, and Chang-Zhi Dong, and Bernard Meunier
Design, synthesis and biological evaluation of novel thiazole-based derivatives as human Pin1 inhibitors.
January 2021, Bioorganic & medicinal chemistry,
Yong-Liang Li, and Long-Jia Yan, and Hui-Xiong Chen, and Ban-Kang Ruan, and Pascal Dao, and Zhi-Yun Du, and Chang-Zhi Dong, and Bernard Meunier
Design, Synthesis, and Biological Evaluation of C-2 Substituted 3Hthieno[ 2,3-d]pyrimidin-4-one Derivatives as Novel FGFR1 Inhibitors.
January 2017, Medicinal chemistry (Shariqah (United Arab Emirates)),
Yong-Liang Li, and Long-Jia Yan, and Hui-Xiong Chen, and Ban-Kang Ruan, and Pascal Dao, and Zhi-Yun Du, and Chang-Zhi Dong, and Bernard Meunier
Design and synthesis of phenylisoxazole derivatives as novel human acrosin inhibitors.
July 2014, Bioorganic & medicinal chemistry letters,
Yong-Liang Li, and Long-Jia Yan, and Hui-Xiong Chen, and Ban-Kang Ruan, and Pascal Dao, and Zhi-Yun Du, and Chang-Zhi Dong, and Bernard Meunier
Design, Synthesis, and Biological Evaluation of Novel Thienopyrimidine Derivatives as PI3Kα Inhibitors.
September 2019, Molecules (Basel, Switzerland),
Yong-Liang Li, and Long-Jia Yan, and Hui-Xiong Chen, and Ban-Kang Ruan, and Pascal Dao, and Zhi-Yun Du, and Chang-Zhi Dong, and Bernard Meunier
Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors.
January 2021, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!